STOCK TITAN

Ainos signs $9M AI NOSE sales agreement with ASE

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

On November 12, 2026, Ainos, Inc. (AIMD) entered into an agreement with ASE Technology Holding Co., Ltd. for the sale of 5,000 AI NOSE units at a total purchase price of US$9,000,000. Ainos described it as its largest single purchase order by value. The agreement follows delivery of 1,400 systems under a previous $2.1 million agreement.

ASE must pay a US$4,500,000 deposit, equal to 50% of the purchase price, within 60 days after signing. The remaining 50% is payable after Ainos completes delivery of all equipment and submits delivery and billing documents. Ainos said revenue will be recognized as contractual performance obligations are satisfied under applicable accounting standards.

The agreement also provides for annual maintenance fees covering platform usage, technical updates and AI algorithm upgrades while ASE owns and uses the equipment. Fees begin the day after the first anniversary of each unit’s delivery acceptance. Delivery schedules, batches and locations will be confirmed in writing under ASE’s deployment plan.

Filing Explained

The agreement requires a $4,500,000 deposit within 60 days; separately, Ainos reported $660,916 in cash at September 30, 2026, equal to 60.9 days of its latest quarterly operating cash outflow at that rate.

Sources and calculations
  • Available liquidity against the last reported quarterly operating outflow, in days at that rate $660,916 / ($997,923 / 92) = 60.9 days
Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Purchase price US$9,000,000 Total price for 5,000 AI NOSE units under the ASE agreement
Equipment units 5,000 units AI NOSE equipment covered by the agreement
Deposit US$4,500,000 50% of the purchase price, due within 60 days after signing
Remaining payment 50% Payable after delivery of all equipment and submission of delivery and billing documents
Previously delivered systems 1,400 systems Delivery under the prior ASE agreement
Prior agreement $2.1 million Agreement under which Ainos completed delivery of 1,400 systems
Chemical data points More than 3 billion Real-world chemical data points accumulated by the AI Nose platform
Chemical Intelligence technical
"physical edge node for Chemical Intelligence"
edge node technical
"As a physical edge node for Chemical Intelligence"
contractual performance obligations financial
"as contractual performance obligations are satisfied"
Smell ID data technical
"machine-readable Smell ID data"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How large is AIMD’s AI Nose order with ASE?

Ainos agreed to sell ASE 5,000 AI NOSE units for US$9,000,000. Ainos described the purchase as its largest single purchase order by value and said it follows delivery of 1,400 systems under a previous $2.1 million agreement.

When do maintenance fees start for the AIMD-ASE equipment?

The annual maintenance fee begins the day after the first anniversary of each unit’s delivery acceptance, and applies for as long as ASE owns and uses the equipment. It covers platform usage, technical updates and AI algorithm upgrade services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001014763 0001014763 2026-11-12 2026-11-12 0001014763 AIMD:CommonStockParValue0.01PerShareMember 2026-11-12 2026-11-12 0001014763 AIMD:WarrantsToPurchaseCommonStockMember 2026-11-12 2026-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 12, 2026

 

AINOS, INC.

 

(Exact name of registrant as specified in its charter)

 

Texas   001-41461   75-1974352

(State or other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

3050 Post Oak Blvd, Suite 510-T80, Houston, TX 77056

(281) 898-6586

(Address and telephone number, including area code, of registrant’s principal executive offices)

 

 

(Former name or former address if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   AIMD   The Nasdaq Stock Market LLC
Warrants to purchase Common Stock   AIMDW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 1.01 Entry into a Material Definitive Agreement

 

On November 12, 2026, Ainos, Inc. (the “Company”), entered into an AI NOSE Equipment Sale and Purchase Agreement (the “Agreement”) with ASE Technology Holding Co., Ltd. (“ASE”). Under the Agreement, the Company agreed to sell, and ASE agreed to purchase, a total of 5,000 units of the Company’s AI NOSE equipment (the “Equipment”). The delivery schedule, batches and locations will be confirmed in writing by the parties in accordance with ASE’s deployment plan.

 

Pursuant to the Agreement, the total purchase price of the Equipment is US$9,000,000. ASE is required to pay a deposit equal to 50% of the total purchase price, or US$4,500,000, within 60 days after the date the Agreement is signed. The remaining 50% is payable after the Company completes delivery of all of the Equipment and submits delivery and billing documents to ASE.

 

In addition, pursuant to the Agreement, beginning on the day after the first anniversary of the delivery acceptance date of each unit, and for so long as ASE owns and uses the Equipment, ASE will pay the Company ongoing annual maintenance fee, covering platform usage, technical updates and AI algorithm upgrade services.

 

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, an English translation of which is filed with this current report on Form 8-K as Exhibit 10.1 and is hereby incorporated herein by reference.

 

Item 7.01 Regulation FD Disclosure

 

On November 12, 2026, the Company announced the execution of the Agreement with ASE. A copy of the press release issued by the Company in this connection is furnished herewith as Exhibit 99.1.

 

The information furnished with this Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act.

 

Item 9.01 Financial Statement and Exhibits

 

(d) Exhibits.

 

Exhibit No.   Description
10.1*   English Translation of AI Nose Equipment Sale and Purchase Agreement, dated November 12, 2026
99.1   Press Release dated November 12, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

* Certain portions of this Exhibit were redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. The Company hereby agrees to furnish a copy of any omitted portion to the Securities and Exchange Commission upon request.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Ainos, Inc.
   
Date: November 17, 2026 By: /s/ Chun-Hsien Tsai
  Name: Chun-Hsien Tsai
  Title: Chief Executive Officer

 

 

 

 

Exhibit 99.1

 

Ainos Secures Largest Order in Company History: $9 Million ASE Agreement for 5,000 Additional AI Nose Systems

 

Follow-on order marks progression from field validation and first-phase delivery to scaled commercial adoption of Chemical Intelligence in advanced packaging $4.5 million deposit payable within 60 days of signing will support order fulfillment and working capital

 

Ainos, Inc. (NASDAQ:AIMD, AIMDW) (“Ainos” or the “Company”) today announced that it has signed a $9 million purchase agreement with ASE Technology Holding Co., Ltd. (“ASE”) for 5,000 additional AI Nose systems. The agreement represents the largest single purchase order by value in Ainos’ history and marks a new phase of commercial scale for its Chemical Intelligence platform in advanced semiconductor manufacturing.

 

The purchase builds on the completed delivery of 1,400 systems under the companies’ previous $2.1 million agreement. At approximately 4.3 times the value of the prior $2.1 million agreement, ASE’s expanded commitment follows experience with the initial deployment and deepens the companies’ commercial relationship. It also provides tangible evidence of Ainos’ progression from concept development and field validation to initial delivery and scaled commercial adoption.

 

Under the agreement, ASE will pay a 50% deposit of $4.5 million within 60 days of signing. The remaining 50% is payable with a payment request submitted after delivery and supported by delivery documentation. This structure will support order fulfillment and working capital needs, while the agreement establishes a larger revenue base for the Company. Revenue will be recognized in accordance with applicable accounting standards as contractual performance obligations are satisfied.

 

“From field validation and first-phase delivery to ASE’s expanded purchase, this record order demonstrates how Chemical Intelligence is progressing from technology development to a business operating at greater scale,” said Eddy Tsai, Chairman and Chief Executive Officer of Ainos. “Our customer’s larger commitment deepens the relationship and provides a revenue foundation and funding to support our next stage of growth. We are focused on delivering these systems and continuously improving our products so that chemical information can create greater value in process stability, yield improvement and worker safety.”

 

“As advanced packaging technologies evolve, ASE continues to advance smart manufacturing through new sensing capabilities,” said a senior executive of ASE. “Together with Ainos, we are expanding chemical sensing coverage to develop a more comprehensive view of conditions across our manufacturing operations. Our joint effort aims to integrate chemical insights with existing manufacturing data to support better-informed decisions on yield and quality, operational efficiency, and personnel safety.”

 

Supporting Yield, Efficiency and Safety in Advanced Packaging

 

Advanced packaging places stringent demands on process consistency, contamination control and product reliability. As a physical edge node for Chemical Intelligence, AI Nose converts airborne chemical signals into digital information that can be analyzed. It helps engineering teams establish environmental baselines, compare chemical conditions across locations, and track where anomalies emerge and how they evolve—complementing existing process and equipment data.

 

The expanded deployment will broaden chemical sensing coverage across relevant ASE manufacturing environments, supporting three target objectives:

 

●Yield and quality: Support contamination management and anomaly investigation, helping teams maintain stable process environments and informing efforts to improve yield and product reliability.

 

●Efficiency and profitability: Identify environmental changes that may contribute to defects, rework or unplanned downtime, supporting efforts to reduce production losses and improve operational efficiency.

 

●Worker and facility safety: Support the identification of, and response to, chemical leaks or abnormal releases, helping teams reduce the risk of personnel exposure, equipment damage and operational disruption.

 

Real-World Data Supports Continuous Improvement and Semiconductor Expansion

 

Ainos’ AI Nose platform has accumulated more than 3 billion real-world chemical data points. These data and field experience provide a foundation for ongoing improvements in system stability, chemical signal analysis and application development. Broader deployment also advances the Company’s Chemical Intelligence and Scent AI strategy: physical sensing nodes collect real-world data to support model learning and product improvement, with customer value providing the foundation for wider adoption. Data use will remain subject to customer permissions and protection requirements, and product performance will be validated under application-specific conditions.

 

 
 

 

In front-end wafer fabrication, Ainos announced in September 2026 that it had begun receiving initial commercial orders following technical validation. The expansion in advanced packaging, together with commercial progress in front-end manufacturing, broadens the Company’s semiconductor business foundation. It also provides experience that can support engagement with additional international customers and the development of monitoring applications in other industrial and healthcare environments, with new applications subject to validation against their specific requirements.

 

About AI Nose

 

AI Nose digitizes scent and chemical signals into machine-readable Smell ID data. Combining proprietary sensing hardware, edge AI, cloud-based fleet management, and a growing library of real-world chemical data, AI Nose enables machines to detect, distinguish, and learn from environmental signals that conventional vision and audio systems cannot capture. Ainos is developing AI Nose as a foundation for Chemical Intelligence across semiconductor manufacturing, robotics, industrial monitoring, healthcare, and other Physical AI applications.

 

 

About Ainos, Inc.

 

Ainos, Inc. (NASDAQ:AIMD) is building Chemical Intelligence for Physical AI, giving machines a new way to understand the physical world by turning chemical signals in the air into digital information. Its AI Nose technology enables intelligent systems to sense and interpret changes in their surroundings, while Atmosphere Engine extends that intelligence toward environmental control. Together, they form a sensing-to-control architecture designed to help machines sense, understand, and ultimately optimize their environments across semiconductor manufacturing, robotics, industrial systems, healthcare environments, and other real-world applications where AI increasingly interacts with the physical world. Follow Ainos on X, formerly known as Twitter, @AinosInc, and LinkedIn to stay up to date. Visit Ainos’ media room at https://ainos.suite.accessnewswire.com.

 

Forward-Looking Statements

 

Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the uncertainty of the contemplated collaboration framework and the expected receipt of license fees, manufacturing license fees and other consideration thereunder; our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our licensed indications and product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.

 

Investor Relations

ir@ainos.com

 

 

 

Filing Exhibits & Attachments

6 documents

Keep reading